Abbreviations
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CDK

:   cyclin-dependent kinase

CDKN1B, cyclin-dependent kinase inhibitor 1B (p27

:   Kip1)

NSCLC

:   non-small cell lung cancer

PUM1/2

:   pumilio RNA-binding family member 1/2

SKP2, S-phase kinase-associated protein 2

:   E3 ubitiquitin ligase

Oncosuppressor miRNAs have emerged as powerful post-transcriptional inhibitors of genetic programs controlling cancer cell proliferation, survival, invasion, metastasis, and stemness. Moreover, the *in vivo* inhibition of tumor growth achieved in mouse cancer models by re-expression of well-characterized tumor suppressor miRNAs, such as miR-34 and let-7, suggests strong therapeutic potential.

Experimentally validated bioinformatics analyses show that cell cycle components are highly enriched among targets of the major tumor suppressor miRNAs. Several G1- and S-phase cyclins (D1, D3, and E2) and cyclin-dependent kinases (CDK4 and CDK6) represent key targets of let-7, miR-15/16, and miR-34 families. Conversely, several oncomiRs target the expression of CDK inhibitors; for example members of the miR-17--92 and miR-106b--25 oncogenic clusters target the p21^CIP1^ transcript.

The CDK inhibitor p27^KIP1^ is lost or inactivated in cancer cells by multiple mechanisms, including decreased synthesis, increased proteolysis, and mislocalization. The p27^KIP1^ and p57^KIP2^ transcripts are critical targets of the closely related miR-221 and miR-222 oncomiRs, which are overexpressed in multiple solid tumors including non-small cell lung cancer (NSCLC).

Downregulation of miR-340 has been reported in multiple tumors such as breast, colon, neuroblastoma, and osteosarcoma, in which mR-340 expression positively correlates with better prognosis. Experimentally validated miR-340 targets include disparate cellular components such as the tyrosine kinase MET in breast cancer,[@cit0001] the transcription factors SOX2 in neuroblastoma[@cit0002] and MITF in melanoma,[@cit0003] and the cytoskeletal regulator ROCK1 in osteosarcoma.[@cit0004]

We recently characterized miR-340 as a novel tumor suppressor in lung cancer and glioblastoma. miR-340 expression inversely correlates with clinical staging in NSCLC patients, whereas exogenous miR-340 inhibits proliferation and survival in NSCLC-derived cells. miR-340--induced growth arrest correlates with p27^KIP1^ accumulation in both lung adenocarcinoma and glioblastoma cells. In A549 cells miR-340 controls p27^KIP1^ at both translational and post-translational levels by directly targeting 3 negative regulators of p27^KIP1^ (PUM1, PUM2, and SKP2) ([**Fig. 1**](#f0001){ref-type="fig"}).[@cit0005] Figure 1.Mechanisms by which miR-340 inhibits the growth of lung cancer cells. miR-340 induces p27 at the translational level by targeting the RNA-binding proteins (PUM1 and PUM2) required for miR-221/222--mediated inhibition of the p27 transcript. miR-340 also induces p27 stabilization by targeting the SKP2 ubiquitin ligase in A549 cells. The blue lines indicate both validated (solid lines: PUM1, PUM2, and SKP2) and preliminarily characterized (dashed lines: cyclins D1 and D2) miR-340 target transcripts in A549 cells.

Human *PUM1* and *PUM2* genes encode 2 evolutionary conserved RNA-binding proteins related to the Pumilio gene products in *Drosophila* and fem-3 in *C. elegans*. The functional role of the PUM1/2 binding sites has been characterized for only a few human transcripts. Binding of PUM1 to the p27^KIP1^ 3′-UTR induces a conformational switch that positively controls miR-221/222 accessibility. PUM2 has been suggested to act redundantly with PUM1. Consequently, p27^KIP1^ expression is affected by PUM1/2 expression levels. Growth factor-induced phosphorylation of PUM1 Ser714 increases its RNA-binding activity, suggesting a role of PUM1 post-translational modification in the control of cell cycle re-entry.[@cit0006]

The *PUM1* and *PUM2* transcripts share miR-340 target elements in their otherwise divergent 3′-UTRs. Our results show that miRNA-mediated downregulation of PUM1 and PUM2 antagonizes the miR-221/222--mediated inhibition of p27^KIP1^. Remarkably, transcriptome-wide analyses of PUM1- and PUM2-bound mRNAs show significant enrichment for multiple cell cycle regulators in addition to p27^KIP1^. Therefore, the miR-340--PUM1/2 axis might control cell cycle progression by targeting multiple transcripts in addition to *CDKN1B*, which encodes p27^KIP1^.[@cit0007] For example, PUM1/2 have also been implicated in the miRNA-mediated control of the cell cycle regulator E2F3 in bladder cancer cells.[@cit0008]

PUM1 belongs to a growing list of RNA-binding proteins including HuR, Dnd1, CRD-BP, and PTB that are implicated in the modulation of miRNA targeting in mammalian cells. Interestingly, the miR-340 target site in the *MITF* 3′-UTR is controlled by the CRD-BP RNA-binding protein, which interferes with miR-340 binding thus protecting the *MITF* transcript from miR-340--mediated degradation.[@cit0003] Intriguingly, in addition to PUM1/2, miR-340 also targets 2 distinct RNA-binding proteins, PBP1/hnRNP1 and hnRNPA2, in colorectal cancer, suggesting a complex interplay between miR-340 and RNA-binding proteins in cancer.[@cit0009]

p27^KIP1^ levels largely depend on protein stability, which is reduced by SCF^SKP2^-mediated ubiquitylation. Through investigation of the mechanism of p27^KIP1^ stabilization in miR-340-overexpressing cells we have identified S-phase kinase-associated protein 2, E3 ubitiquitin ligase (SKP2), the substrate-recognizing component of the SCF^SKP2^ complex, as a target of miR-340. To our knowledge, this is the first evidence of miRNA-mediated regulation of the human SKP2 oncoprotein. In summary, in NSCLC cells miR-340 induces p27^KIP1^ accumulation by affecting both synthesis (through PUM1/2) and degradation (through SKP2) of the CDK inhibitor.

Single nucleotide polymorphisms (SNPs) or 3′-UTR shortening events are known to affect the miRNA binding sites of transcripts coding for oncoproteins, such as KRAS. The identification of a *SKP2* mRNA species harboring a short 3′-UTR lacking the miR-340 target site suggests that, depending on the splicing pattern, some tumors could express a SKP2 transcript isoform that is resistant to miR-340--mediated repression.

Similar mechanisms might affect the p27^KIP1^ and/or PUM1/2 3′-UTRs. Interestingly, we have identified cell lines in which p27^KIP1^ is unaffected by miR-340. Since miR-340 retains its antiproliferative activity in these cell lines, we investigated other putative miR-340 targets. Among various oncogenically relevant target transcripts, our preliminary experiments identified both cyclin D1 and cyclin D2, whose expression shows a significant inverse correlation with that of the miR-340 host gene (*RNF130*). Therefore, miR-340 could influence G1/S transition by affecting the accumulation of cyclins D1/D2 and the activity of cyclin D/CDK4/6 complexes, together with the induction of p27^KIP1^ (via PUM1/2 and SKP2) and inhibition of the cyclin E/CDK2 complex. In addition, having observed that miR-340 is responsive to serum induction we postulate that miR-340 might participate in the control of cell cycle progression in response to extracellular mitogenic signals.

In addition to further studies aimed at the transcriptome-wide identification of target mRNAs and oncogenic networks modulated by miR-340, future investigations will address the applications of miR-340. Importantly, systemic delivery of pre-miR-340 has recently been shown to inhibit the growth of xenografts of human colorectal cancer cells in mice.[@cit0010] Therefore, multiple lines of evidence point to miR-340 as a novel, highly promising bullet for miRNA-based anticancer therapeutics.
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